Join pharmaphorum for an insightful webinar, presented by EVERSANA INTOUCH, featuring Denise Dalton, vice president of ...

For clinical research to be truly reflective of our populations, DEI-oriented strategies need to take higher priority in ...

Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, ...

Novo Nordisk chief executive Lars Fruergaard Jørgensen was taken to task by US lawmakers over the price of the company's ...

The ESMO congress always disseminates the latest results of cancer research, a vibrant gathering and sharing of the latest data, communicating the next promising steps in oncological scientific ...

Phase 2 results with Wave Life Sciences' Duchenne muscular dystrophy candidate WVE-N531 pushed the company's share price to ...

Shares in Wave rose 53% after the trial data was announced, taking its market cap above the $1 billion threshold. The company ...

Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai ...

The wide-ranging deal, worth up to $1 billion, covers multiple targets and disease areas and focuses on the discovery and ...

The ESMO congress always disseminates the latest results of cancer research, a vibrant gathering and sharing of the latest ...

Dr Paul Campbell, head of software and AI at the MHRA, said in a recent webinar that AIaMD has the potential to "fix some of ...

Vyloy (zolbetuximab) has been given the go-ahead for use in combination with chemotherapy for the first-line treatment of ...